Bio-Gene TechnologyASX:BGT ROA % is -154.64% as of Dec. 2025. The stock has 2 warning signs investors should review. Among 1,423 Biotechnology companies, Bio-Gene Technology ranks worse than 89.04% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Bio-Gene Technology's annualizedNet Income for the quarter that ended in Dec. 2025 was A$-2.80 Mil.
Bio-Gene Technology's average Total Assets over the quarter that ended in Dec. 2025 was A$1.81 Mil. Therefore, Bio-Gene Technology's annualized ROA % for the quarter that ended in Dec. 2025 was -154.64%.
The historical rank and industry rank for Bio-Gene Technology's ROA % or its related term are showing as below:
ASX:BGT'
s ROA % Range Over the Past 10 Years
Min: -137.71 Med: -44.39 Max: -31.08
Current: -137.71
During the past 8 years, Bio-Gene Technology's highest ROA % was -31.08%. The lowest was -137.71%. And the median was -44.39%.
ASX:BGT's ROA % is ranked worse than 89.04% of 1423
companies
in the Biotechnology industry
Industry Median: -33.07
vs ASX:BGT: -137.71
Bio-Gene Technology (ASX:BGT) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Bio-Gene Technology ROA % Related Terms
Bio-Gene Technology ROA % Historical Data
* Premium members only.
The historical data trend for Bio-Gene Technology's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Bio-Gene Technology's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio-Gene Technology ROA % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bio-Gene Technology's ROA % distribution charts can be found below:
* The bar in red indicates where Bio-Gene Technology's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
ROA % is displayed in the 30-year financial page.
Bio-Gene Technology (ASX:BGT) has a ROA % of -154.64% as of Dec. 2025. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Bio-Gene Technology and its competitors. According to the industry distribution chart, Bio-Gene Technology ranks #1267 out of 1423 companies in the Biotechnology industry, placing it in the top 89%.
Is Bio-Gene Technology's ROA % too high?
Bio-Gene Technology's current ROA % is -154.64%. Based on the distribution chart, Bio-Gene Technology ranks #1267 out of 1423 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Bio-Gene Technology's ROA % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Bio-Gene Technology ranks #1267 out of 1423 companies for ROA %. This places Bio-Gene Technology in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Biotechnology company?
A good ROA % depends on the Biotechnology industry context. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Bio-Gene Technology and its competitors. Bio-Gene Technology's current ROA % is -154.64%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Gene Technology stock overvalued right now?
Bio-Gene Technology (ASX:BGT) has a current ROA % of -154.64%. The current ROA % is -154.64%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Bio-Gene Technology (ASX:BGT), the current ROA % is -154.64% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bio-Gene Technology Ltd is an Australian company developing novel bio-insecticides to address the challenges of insecticide resistance and toxicity. Its products are based on a naturally occurring class of compounds to overcome resistance to control pests with minimal impact on human health and the environment. Bio-Gene's products have multiple applications across public health, crop protection, grain storage, and consumer use. The company operates in one business segment, being the conduct of research and development activities in the discovery of novel insecticides.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:BGT has been successfully added to your 